A Randomized Controlled Trial Evaluating the Effectiveness of Contrave (Naltrexone HCl and Bupropion HCl) in Patients Who Have Weight Recidivism Following Bariatric Surgery: Contrave Obesity Trials (COR) Weight Regain Study
Latest Information Update: 07 Aug 2023
At a glance
- Drugs Naltrexone/bupropion (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms COR-WR
- 01 Aug 2023 Planned End Date changed from 15 May 2023 to 31 Dec 2023.
- 01 Aug 2023 Planned primary completion date changed from 15 May 2023 to 30 Dec 2023.
- 01 Aug 2023 Status changed from not yet recruiting to active, no longer recruiting.